Abstract
Experimental and clinical study of cefodizime (CDZM, THR-221), a newly developed cephem antibiotic, was done in the field of pediatrics and the results obtained are summarized as follows:
1. Serum levels and urine excretion were examined after 60-minute drip infusion of CDZM at a dose level of 10mg/kg to 1 patient, at 20mg/kg to 4 and at 40mg/kg to 1. Peak levels in serum were 66.3μg/ml for the 10mg/kg dose occurring 1 hours after the dose, 118.1μg/ml (mean) for 20mg/kg, 259.2μg/ml for 40mg/kg, thus a dose-response was observed.
T 1/2's (beta phase) were between 1.17 and 1.69 hours. Urinary recovery rates of the drug were between 71.5% and 98.0% in the first 8 hours after administration.
2. The concentration in the cerebrospinal fluid was 0.76μg/ml and the serum level was 380.67μg/ml at 15 minutes after intravenous administration of 433mg of CDZM to a patient with purulent meningitis.
3. The clinical efficacy rate was 95.2% in a total of 21 cases, i. e., 1 purulent meningitis, 10 respiratory tract infection, 3 whooping cough, 5 urinary tract infection, 1 purulent infection of soft tissues and 1 acute thyroiditis.
Diarrhea occurred in 1 case as adverse reactions. Abnormal changes in laboratory test results occurred as 1 case each of slightly elevated GOT·GPT and GOT.
